ArticleJournal of cell communication and signaling2009
SPARC: a matricellular regulator of tumorigenesis.
Article in Journal of cell communication and signaling, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 174 citations in OpenAlex.
- A single bout of resistance or high-intensity interval training increases anti-cancer myokines and suppresses cancer cell growth in vitro in survivors of breast cancer.Breast cancer research and treatment · 2025Trial
- Exploring platelet-covered and naked circulating tumor cells - a single-cell transcriptomic perspective.Journal of translational medicine · 2026Article
- Review
- SPARC is associated with tumor nerve stroma interactions and perineural invasion in pancreatic ductal adenocarcinoma.Scientific reports · 2026Article
- Human Serum Albumin as a Prodrug Carrier for Tumor Therapy: Mechanisms, Applications, and Future Perspectives.Pharmaceutics · 2026Review
- Transcriptome-wide analysis of genes associated with collagen III in human skin.American journal of translational research · 2026Article
- Regulatory Mechanisms of SPARC Overexpression in Melanoma Progression.International journal of molecular sciences · 2025Article
- Systematic profiling of cancer-fibroblast interactions reveals drug combinations in ovarian cancer.Molecular oncology · 2025Article
- Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy.Breast cancer research : BCR · 2025Article
- Pre-diagnostic Demographic, Lifestyle, and Health History Factors in Association with Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression in Colorectal Cancer Tissue.Biomarker insights · 2025Article
- Matricellular proteins in immunometabolism and tissue homeostasis.BMB reports · 2024Review
- HDAC10 inhibition represses melanoma cell growth and BRAF inhibitor resistance via upregulating SPARC expression.NAR cancer · 2024Article
- Therapeutic effects of in vivo administration of an inhibitor of tryptophan 2,3-dioxygenase (680c91) for the treatment of fibroids: a preclinical study.Fertility and sterility · 2024Article
- Hic-5 regulates extracellular matrix-associated gene expression and cytokine secretion in cancer associated fibroblasts.Experimental cell research · 2024Article
- Effects of Exercise-Induced Changes in Myokine Expression on the Tumor Microenvironment.Sports medicine international open · 2024Review
- Cell-type-specific alternative polyadenylation as a therapeutic biomarker in lung cancer progression.Molecular therapy. Nucleic acids · 2023Article
- Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.Scientific reports · 2023Article
- Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression.Molecular therapy. Nucleic acids · 2023Article
- Omics Overview of the SPARC Gene in Mesothelioma.Biomolecules · 2023Review
- Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Although many clinical studies have found a correlation of SPARC expression with malignant progression and patient survival, the mechanisms for SPARC function in tumorigenesis and metastasis remain elusive. The activity of SPARC is context- and cell-type-dependent, which is highlighted by the fact that SPARC has shown seemingly contradictory effects on tumor progression in both clinical correlative studies and in animal models. The capacity of SPARC to dictate tumorigenic phenotype has been attributed to its effects on the bioavailability and signaling of integrins and growth factors/chemokines. These molecular pathways contribute to many physiological events affecting malignant progression, including extracellular matrix remodeling, angiogenesis, immune modulation and metastasis. Given that SPARC is credited with such varied activities, this review presents a comprehensive account of the divergent effects of SPARC in human cancers and mouse models, as well as a description of the potential mechanisms by which SPARC mediates these effects. We aim to provide insight into how a matricellular protein such as SPARC might generate paradoxical, yet relevant, tumor outcomes in order to unify an apparently incongruent collection of scientific literature.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.